Spyre Therapeutics, Inc. (SYRE) Stock

Spyre Therapeutics, Inc. (SYRE) is a Healthcare stock trading at $97.35 (as of 2026-07-20), with a market capitalization of $8.45B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Understand Spyre Therapeutics, Inc.: how it makes money

Spyre Therapeutics develops monoclonal antibody therapies for inflammatory bowel disease, it aims to generate future revenue if its drug candidates such as SPY001, SPY002, and the combination SPY120 successfully progress through clinical development.

Because Spyre Therapeutics is a preclinical stage biotechnology company focused on developing SPY001, SPY002, and SPY120, its potential profit engine is tied to clinical progress (efficacy endpoints and safety) rather than current product sales.

Business quality (Weak): Preclinical-stage focus with no reported revenue in the provided period, so near-term outcomes rely on clinical endpoint performance and safety for SPY001 and SPY002.

Bull case

SPY002 shows efficacy signals in the reported metrics: Reported SPY002 clinical remission rate is 33% and endoscopic improvement rate is 42%.
Safety reporting includes no reported drug-related serious adverse events: Reported drug-related serious adverse events are 0.0 (count), and severe grade 3 or greater adverse events are 4.2 (count).

Bear case

SPY001 primary endpoint statistical signal is reported as 0.0: The label 'Primary endpoint p-value Robart's Histopathology Index reduction' is 0.0 (ratio).
Treatment-emergent and discontinuation events are present in the reported safety metrics: Reported subjects with any treatment-emergent adverse events are 41.7% and adverse events leading to drug discontinuation are 4.2%.
No revenue is reported in the provided period: For the period ended 2023-06-30, revenue is 0.0B, and operating margin is -23146.2%.

Valuation — source: SEC EDGAR (first-party)
Price	$97.35
Market Cap	$8.45B
Price / Book	12.60

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Revenue Growth (YoY)	-100.0%
FCF Growth (YoY)	57.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	71.54 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.1
Industry P/E (Pharmaceutical Products)	16.8

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($594.23M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Cameron Turtle
Employees	73
Country	US
IPO Date	2016-04-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-07-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.